Know Labs Inc. (KNW) is a U.S.-based company specializing in the development and commercialization of non-invasive medical diagnostics technologies. Their primary focus is on creating devices that utilize their proprietary Bio-RFID™ technology to detect and measure various analytes in the human body without the need for invasive procedures.
Key Strategic Focus
Know Labs is dedicated to revolutionizing medical diagnostics through non-invasive methods. Their core objective is to leverage Bio-RFID™ technology to provide real-time, accurate measurements of physiological parameters, thereby enhancing patient care and monitoring. The company targets markets such as diabetes management, aiming to offer alternatives to traditional blood glucose monitoring systems.
Financials and Funding
As of June 3, 2025, Know Labs Inc. (KNW) is publicly traded on the USA market. The stock is priced at $0.487 per share, reflecting a slight decrease of $0.0062 (-1.25%) from the previous close. The day's trading saw a high of $0.55 and a low of $0.4701, with an opening price of $0.4983 and a volume of 324,927 shares. The latest trade was recorded at 00:19:02 UTC.
Pipeline Development
Know Labs is actively developing non-invasive diagnostic devices utilizing their Bio-RFID™ technology. These devices are designed to measure various analytes, including blood glucose levels, without the need for traditional blood draws. The company is progressing through clinical trials and product development stages, aiming to achieve regulatory approvals and market entry in the near future.
Technological Platform and Innovation
At the heart of Know Labs' innovation is their proprietary Bio-RFID™ technology. This platform employs radiofrequency identification to detect and measure specific molecules within the body non-invasively. By harnessing this technology, Know Labs aims to provide accurate, real-time health data, setting them apart in the medical diagnostics industry.
Leadership Team
- Ron Erickson: Founder and CEO, bringing extensive experience in technology and business development.
- Phil Bosua: Chief Technology Officer, leading the technological advancements and product development initiatives.
- Steve Kent: Chief Financial Officer, overseeing the company's financial strategy and operations.
Leadership Changes
There have been no recent significant changes or appointments within the company's leadership team.
Competitor Profile
Market Insights and Dynamics
The non-invasive medical diagnostics market is experiencing significant growth, driven by increasing demand for painless and convenient monitoring solutions, particularly in chronic disease management. Advancements in technology and a focus on patient-centric care are propelling this market forward.
Competitor Analysis
Key competitors in the non-invasive diagnostics space include companies like Dexcom and Abbott Laboratories, both of which offer continuous glucose monitoring systems. These companies focus on providing real-time glucose data to patients, enhancing diabetes management. Know Labs differentiates itself by utilizing Bio-RFID™ technology, aiming to offer a unique, non-invasive solution in this competitive landscape.
Strategic Collaborations and Partnerships
Know Labs has engaged in strategic collaborations with research institutions and healthcare organizations to validate and enhance their Bio-RFID™ technology. These partnerships are instrumental in advancing clinical trials and facilitating the integration of their devices into existing healthcare systems.
Operational Insights
In the competitive landscape of non-invasive diagnostics, Know Labs' Bio-RFID™ technology offers a distinct advantage by providing real-time, accurate measurements without the need for invasive procedures. This positions the company favorably against competitors relying on traditional monitoring methods.
Strategic Opportunities and Future Directions
Looking ahead, Know Labs aims to expand its product portfolio to address a broader range of analytes and health conditions. By leveraging their Bio-RFID™ platform, the company seeks to enter new markets and establish itself as a leader in non-invasive diagnostics. Continued investment in research and development, along with strategic partnerships, will be key to achieving these objectives.
Contact Information
Please note that specific contact details such as physical address, phone number, or email are not provided in this profile.
